MCID: BRR013
MIFTS: 53

Barrett Esophagus/esophageal Adenocarcinoma

Categories: Genetic diseases, Rare diseases, Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Barrett Esophagus/esophageal Adenocarcinoma

MalaCards integrated aliases for Barrett Esophagus/esophageal Adenocarcinoma:

Name: Barrett Esophagus/esophageal Adenocarcinoma 54 13
Barrett Esophagus 12 50 24 71 52 42 69
Barrett's Esophagus 12 50 29 14
Adenocarcinoma of Esophagus 24 56 69
Barrett's Ulcer of Esophagus 12 69
Barrett Metaplasia 24 71
Chronic Peptic Ulcer and Esophagitis Syndrome 50
Barrett's Esophagus with Esophagitis 12
Malignant Neoplasm of Esophagus 69
Esophageal Adenocarcinoma 56
Esophagitis-Peptic Ulcer 50
Columnar-Like Esophagus 50
Esophageal Carcinoma 69
Barrett's Oesophagus 12
Esophageal Neoplasms 69
Esophageal Cancer 24
Barretts Syndrome 12
Barrett Syndrome 50
Barrett Ulcer 50
Cle 12
Be 71

Characteristics:

Orphanet epidemiological data:

56
adenocarcinoma of esophagus
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/1000000 (Worldwide); Age of onset: Adult; Age of death: adult;

HPO:

32
barrett esophagus/esophageal adenocarcinoma:
Inheritance somatic mutation


Classifications:



External Ids:

OMIM 54 614266
Disease Ontology 12 DOID:9206
ICD9CM 35 530.85
MeSH 42 D001471
NCIt 47 C2891
Orphanet 56 ORPHA99976
UMLS via Orphanet 70 C0279628
ICD10 via Orphanet 34 C15.2 C15.5
UMLS 69 C0004763

Summaries for Barrett Esophagus/esophageal Adenocarcinoma

NIH Rare Diseases : 50 barrett esophagus is a condition in which the lining of the esophagus (the tube that carries food from the throat to the stomach) is replaced by tissue that is similar to the lining of the intestines. although this change does not cause any specific signs or symptoms, it is typically diagnosed in people who have long-term gastroesophageal reflux disease (gerd). the exact underlying cause of barrett esophagus is not known; however, it generally occurs sporadically in people with no family history of the condition. treatment varies by the severity of the condition and generally includes medications and life style modifications to ease the symptoms of gerd. endoscopic or surgical treatments may be recommended in people with severe cases. last updated: 7/13/2015

MalaCards based summary : Barrett Esophagus/esophageal Adenocarcinoma, also known as barrett esophagus, is related to situs inversus and hepatocellular carcinoma, and has symptoms including esophageal carcinoma, barrett esophagus and gastroesophageal reflux. An important gene associated with Barrett Esophagus/esophageal Adenocarcinoma is ASCC1 (Activating Signal Cointegrator 1 Complex Subunit 1), and among its related pathways/superpathways are Pathways in cancer and Cell cycle. The drugs Abstral and Actiq have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and skin, and related phenotypes are digestive/alimentary and homeostasis/metabolism

UniProtKB/Swiss-Prot : 71 Barrett esophagus: A condition characterized by a metaplastic change in which normal esophageal squamous epithelium is replaced by a columnar and intestinal-type epithelium. Patients with Barrett esophagus have an increased risk of esophageal adenocarcinoma. The main cause of Barrett esophagus is gastroesophageal reflux. The retrograde movement of acid and bile salts from the stomach into the esophagus causes prolonged injury to the esophageal epithelium and induces chronic esophagitis, which in turn is believed to trigger the pathologic changes.

OMIM : 54
Barrett esophagus, or Barrett metaplasia, describes the phenotypic change of normal esophageal squamous epithelium to a columnar and intestinal-type epithelium. This metaplastic change is important because patients with Barrett esophagus have an increased risk of esophageal adenocarcinoma. The main cause of Barrett metaplasia is gastroesophageal reflux (GER; 109350). The retrograde movement of acid and bile salts from the stomach into the esophagus in this disease causes prolonged injury to the esophageal epithelium and induces chronic esophagitis, which in turn is believed to trigger the pathologic changes (summary by Wong et al., 2005). (614266)

Related Diseases for Barrett Esophagus/esophageal Adenocarcinoma

Diseases related to Barrett Esophagus/esophageal Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 303)
id Related Disease Score Top Affiliating Genes
1 situs inversus 31.0 MUC2 MUC6
2 hepatocellular carcinoma 29.4 CCND1 CDKN2A GSTP1 KRT7 PTGS2 TP53
3 lung cancer 28.6 CCND1 CDKN2A FHIT GSTP1 KRT20 KRT7
4 colorectal cancer 26.6 AMACR CCND1 CDKN2A CDX2 FHIT GAST
5 esophageal cancer 12.5
6 tylosis with esophageal cancer 12.3
7 high-grade dysplasia in patients with barrett esophagus 12.0
8 esophageal cancer, childhood 11.8
9 emphysema, congenital lobar 11.6
10 prune belly syndrome 11.4
11 mungan syndrome 11.2
12 adenocarcinoma 11.1
13 esophagitis 11.1
14 visceral myopathy 11.0
15 cervical adenoid cystic carcinoma 11.0 CDKN2A TP53
16 leukoencephalopathy with vanishing white matter 11.0
17 skeletal tuberculosis 11.0 CCND1 CDKN2A
18 tendon sheath lipoma 10.9 PTGS2 TP53
19 split hand split foot nystagmus 10.8 CDKN2A TP53
20 esophagus squamous cell carcinoma 10.8 CDKN2A PTGS2 TP53
21 cervical adenitis 10.8 CDKN2A KRT7
22 brachial amelia, forebrain defects and facial clefts 10.8 CCND1 CDKN2A PTGS2
23 lupus erythematosus tumidus 10.8
24 bone giant cell tumor 10.8 KRT20 KRT7
25 neuroendocrine tumor 10.8 CDX2 KRT20 PTGS2
26 active vestibular meniere's disease 10.8 CCND1 CDKN2A PTGS2
27 urinary system disease 10.8 MUC2 MUC6
28 hodgkin lymphoma 10.8
29 retinal dystrophy with inner retinal dysfunction and ganglion cell abnormalities 10.8 CDX2 PTGS2 TP53
30 bladder squamous cell carcinoma 10.8 CCND1 CDKN2A TP53
31 ascending colon cancer 10.8 KRT20 MUC2
32 rectum adenoma 10.8 KRT20 KRT7
33 ductal carcinoma in situ 10.8 CCND1 CDKN2A TP53
34 leiomyoma cutis 10.8 CDKN2A TP53
35 synovitis 10.8 CDX2 KRT7
36 stricture or kinking of ureter 10.8 CDX2 KRT20 MUC2
37 hereditary persistence of fetal hemoglobin, klf1-related 10.8 MUC6 PTGS2
38 cushing's syndrome 10.8 ATP4A CDX2 PTGS2
39 unilateral retinoblastoma 10.8 CCND1 CDKN2A TP53
40 integumentary system cancer 10.8 CCND1 CDKN2A TP53
41 pharynx cancer 10.8 CCND1 CDKN2A TP53
42 childhood oligodendroglioma 10.8 CDKN2A KRT20 TP53
43 periosteal osteogenic sarcoma 10.8 KRT20 KRT7
44 rhinosporidiosis 10.8 CDX2 KRT20
45 hodgkin's lymphoma, mixed cellularity 10.8 CCND1 CDKN2A TP53
46 lipid-cell variant infiltrating bladder urothelial carcinoma 10.8 KRT7 TP53
47 atrophic gastritis 10.8 CDKN2A PTGS2 TP53
48 striated muscle rhabdoid tumor 10.8 KRT20 MUC2 TP53
49 steroid-induced glaucoma - borderline 10.8 KRT20 KRT7
50 post-surgical hypoinsulinemia 10.8 CCND1 CDKN2A TP53

Graphical network of the top 20 diseases related to Barrett Esophagus/esophageal Adenocarcinoma:



Diseases related to Barrett Esophagus/esophageal Adenocarcinoma

Symptoms & Phenotypes for Barrett Esophagus/esophageal Adenocarcinoma

Clinical features from OMIM:

614266

Human phenotypes related to Barrett Esophagus/esophageal Adenocarcinoma:

56 32 (show all 10)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 esophageal carcinoma 56 32 Very frequent (99-80%) HP:0011459
2 barrett esophagus 56 32 Very frequent (99-80%) HP:0100580
3 gastroesophageal reflux 56 Very frequent (99-80%)
4 cough 56 Frequent (79-30%)
5 lymphadenopathy 56 Occasional (29-5%)
6 obesity 56 Very frequent (99-80%)
7 feeding difficulties in infancy 56 Very frequent (99-80%)
8 chest pain 56 Frequent (79-30%)
9 nausea and vomiting 56 Frequent (79-30%)
10 clinodactyly of the 5th toe 56 Very frequent (99-80%)

UMLS symptoms related to Barrett Esophagus/esophageal Adenocarcinoma:


abdominal pain, constipation, coughing, diarrhea, dyspepsia, heartburn, icterus, nausea and vomiting, snoring, sore throat, vertigo/dizziness, equilibration disorder, gastrointestinal gas

MGI Mouse Phenotypes related to Barrett Esophagus/esophageal Adenocarcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.1 ATP12A ATP4A CCND1 CDKN2A CDX2 FHIT
2 homeostasis/metabolism MP:0005376 10.03 AMACR ATP12A ATP4A CCND1 CDKN2A CDX2
3 endocrine/exocrine gland MP:0005379 9.91 ATP4A CCND1 CDKN2A CDX2 GAST MCM2
4 immune system MP:0005387 9.7 MCM2 MSR1 MUC2 MUC5AC PTGS2 TP53
5 neoplasm MP:0002006 9.28 CDKN2A CDX2 FHIT GAST MCM2 MUC2

Drugs & Therapeutics for Barrett Esophagus/esophageal Adenocarcinoma

FDA approved drugs:

(show top 50) (show all 194)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Abstral 17 FENTANYL (citrate) ProStrakan January 2011
2
Actiq 17 FENTANYL (citrate) Anesta Corporation November 1998
3
Adcetris 17 46 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011
4
Afinitor 17 46 EVEROLIMUS Novartis March 2009
5
Akynzeo 17 46 NETUPITANT AND PALONOSETRON (hydrochloride) Helsinn October 2014
6
Aloxi 17 46 PALONOSETRON (hydrochloride) MGI Pharma, Helsinn Healthcare August 2003
7
Anexsia 17 ACETAMINOPHEN; HYDROCODONE BITARTRATE Mallinckrodt Group August 1996
8
Aredia 17 46 PAMIDRONATE DISODIUM Chiron August 1996
9
Arimidex 17 46 ANASTROZOLE AstraZeneca January 1996
10
Aromasin Tablets 17 46 EXEMESTANE Pharmacia & Upjohn October 21. 1999
11
Arranon 17 46 NELARABINE GlaxoSmithKline October 2005
12
Beleodaq 17 46 BELINOSTAT Spectrum Pharmaceuticals July 2014
13
Blincyto 17 46 BLINATUMOMAB Amgen December 2014
14
Busulfex 17 46 BUSULFAN Orphan Medical February 1999
15
Campostar 17 46 IRINOTECAN HYDROCHLORIDE Pharmacia & Upjohn June 1996
16
Cervarix 17 46 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline October 2009
17
Clolar 17 46 CLOFARABINE Genzyme December, 2004
18
Cometriq 17 46 CABOZANTINIB S-MALATE Exelixis November 2012
19
Degarelix 17 46 degarelix Ferring Pharmaceuticals December of 2008
20
Elitek 17 46 RASBURICASE sanofi-aventis October 2009
21
Ellence 17 46 EPIRUBICIN HYDROCHLORIDE Pharmacia & Upjohn September 1999
22
Eloxatin 17 46 OXALIPLATIN Sanofi-aventis August 2002
23
Erwinaze 17 46 asparaginase Erwinia chrysanthemi Eusa Pharma November of 2011
24
Ethyol 17 AMIFOSTINE Alza December 8, 1995
25
Eulexin 17 FLUTAMIDE Schering-Plough June 1996
26
Evista 17 46 RALOXIFENE HYDROCHLORIDE Eli Lilly September 2007
27
Farydak 17 46 PANOBINOSTAT LACTATE Novartis February 2015
28
Faslodex 17 46 FULVESTRANT AstraZeneca April 2002
29
Folotyn 17 46 PRALATREXATE Allos Therapeutics September 2009
30
Fusilev 17 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals March of 2008
31
Gardasil 17 46 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
32
Gemzar 17 46 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996
33
Gilotrif 17 46 AFATINIB DIMALEATE Boehringer Ingelheim July 2013
34
Hycamtin 17 46 TOPOTECAN HYDROCHLORIDE GlaxoSmithKline/ SmithKline Beecham October 2007/May 1996
35
Ibrance 17 46 PALBOCICLIB Pfizer February 2015
36
Iclusig 17 46 PONATINIB HYDROCHLORIDE Ariad Pharmaceuticals December 2012
37
Imbruvica 17 46 IBRUTINIB Pharmacyclics November of 2013/February 2014
38
Inlyta 17 46 AXITINIB Pfizer January 2012
39
Intron A 17 46 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
40
Iressa 17 46 GEFITINIB AstraZeneca May 2003
41
Istodax 17 46 ROMIDEPSIN Gloucester Pharmaceuticals November 2009
42
Ixempra 17 46 IXABEPILONE Bristol-Myers Squibb October 2007
43
Jevtana 17 46 CABAZITAXEL sanofi aventis June 2010
44
Kadcyla 17 46 ADO-TRASTUZUMAB EMTANSINE Genentech February 2013
45
Kadian 17 MORPHINE SULFATE Purepac Pharmaceutical July 1996
46
Keytruda 17 46 PEMBROLIZUMAB Merck September 2014
47
Kyprolis 17 46 CARFILZOMIB Onyx Pharmaceuticals July 2012
48
Lazanda 17 FENTANYL CITRATE Archimedes June 2011
49
Lenvima 17 46 LENVATINIB MESYLATE Eisai February 2015
50
Leukine 17 SARGRAMOSTIM Immunex on November 24, 1995/ November 1996

Drugs for Barrett Esophagus/esophageal Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 67)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Menthol Approved Phase 4 2216-51-5 16666
2
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
3
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
4 Liver Extracts Phase 4
5 Prednisolone acetate Phase 4
6 glucocorticoids Phase 4
7 Methylprednisolone acetate Phase 4
8 Methylprednisolone Hemisuccinate Phase 4
9 Gastrointestinal Agents Phase 4,Phase 3
10 Neuroprotective Agents Phase 4
11 Hormone Antagonists Phase 4,Phase 2
12 Hormones Phase 4,Phase 2
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2
14 Peripheral Nervous System Agents Phase 4,Phase 3
15 Prednisolone hemisuccinate Phase 4
16 Prednisolone phosphate Phase 4
17 Anti-Inflammatory Agents Phase 4,Phase 3
18 Antiemetics Phase 4
19 Protective Agents Phase 4
20 Autonomic Agents Phase 4
21 Antineoplastic Agents, Hormonal Phase 4
22
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
23
Esomeprazole Approved, Investigational Phase 3 161796-78-7, 119141-88-7 4594 9579578
24
Proton pump inhibitors Phase 3
25 Analgesics Phase 3
26 Fibrinolytic Agents Phase 3
27 Cyclooxygenase Inhibitors Phase 3
28 Analgesics, Non-Narcotic Phase 3
29 Antacids Phase 3
30 Platelet Aggregation Inhibitors Phase 3
31 Anti-Inflammatory Agents, Non-Steroidal Phase 3
32 Anti-Ulcer Agents Phase 3
33 Antipyretics Phase 3
34 Antirheumatic Agents Phase 3
35
Trioxsalen Approved Phase 2 3902-71-4 5585
36
Proflavine Approved Phase 2 92-62-6 7099
37 Hematoporphyrin Derivative Phase 2
38 Dihematoporphyrin Ether Phase 2
39 Gastrins Phase 2
40 Anti-Infective Agents Phase 2
41 Anti-Infective Agents, Local Phase 2
42
Mechlorethamine Approved Phase 1 51-75-2 4033
43
Bevacizumab Approved, Investigational Phase 1 216974-75-3
44 Angiogenesis Inhibitors Phase 1
45 Angiogenesis Modulating Agents Phase 1
46 lysine Nutraceutical Phase 1
47
Enalapril Approved, Vet_approved Early Phase 1 75847-73-3 5362032 40466924
48
Enalaprilat Approved Early Phase 1 76420-72-9 6917719
49
Candesartan Approved Early Phase 1 139481-59-7 2541
50
Iron Approved 7439-89-6 23925

Interventional clinical trials:

(show top 50) (show all 52)

id Name Status NCT ID Phase Drugs
1 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
2 Barretts oEsophageal Resection With Steroid Therapy Trial Recruiting NCT02004782 Phase 4 Prednisolone
3 Confocal Endomicroscopy for Barrett's Esophagus Completed NCT00487695 Phase 3
4 A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia Active, not recruiting NCT00357682 Phase 3 Esomeprazole;Esomeprazole;Aspirin
5 Tethered Capsule Endoscope in Screening Participants for Barrett Esophagus Unknown status NCT00903136 Phase 1, Phase 2
6 Endoscopic Therapy of Early Cancer in Barretts Esophagus Completed NCT00217087 Phase 2
7 Photodynamic Therapy in Treating Patients With Precancerous Esophageal Conditions or Early Stage Esophageal Cancer Completed NCT00281736 Phase 2 HPPH
8 Accuracy, Yield and Clinical Impact of a Low-Cost HRME in the Early Diagnosis of Esophageal Adenocarcinoma Recruiting NCT02018367 Phase 2 Proflavine, high resolution imaging
9 Autologous Cell Sheets Transplantation After ESD in the Esophagus Recruiting NCT02455648 Phase 2
10 Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus Recruiting NCT01298999 Phase 2 YF476;Placebo
11 YF476 in Barrett's Esophagus Enrolling by invitation NCT02597712 Phase 2 YF476;YF476 placebo
12 Esophageal Protocol for Detection of Neoplasia in the Digestive Tract Completed NCT01391208 Phase 1 GI heptapeptide
13 A In-Vivo Esophageal Protocol for Detection of Neoplasia in the Digestive Tract Completed NCT01630798 Phase 1 GI heptapeptide
14 VEGF-targeted Fluorescence Near-Infrared (NIR) Endoscopy in (Pre)Malignant Esophageal Lesions Completed NCT02129933 Phase 1 Bevacizumab-IRDye800CW
15 Molecular Fluorescence Endoscopy of (Pre)Malignant Esophageal Lesions Active, not recruiting NCT03205501 Phase 1 IV-administation of EMI-137
16 Studying Genes for Barrett's Esophagus in Brothers and Sisters Unknown status NCT00516347
17 Familial Barrett's Esophagus Unknown status NCT00288119
18 Early Detection of Tumors of the Digestive Tract by Confocal Endomicroscopy Unknown status NCT02284802
19 Confocal Laser Endomicroscopy in Patients With Eosinophilic Esophagitis Unknown status NCT01234376
20 Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management Completed NCT02075905
21 Endoscopic Tri-Modal Imaging in Patients With Barrett's Esophagus Completed NCT00586989
22 Micro-RNA (miR) Expression in Upper Gastrointestinal Mucosal Tissue Completed NCT00909350
23 Preliminary Longitudinal Validation of Biomarkers Predictive of Barrett's Esophagus Completed NCT00844077
24 Early Detection of Barrett's Esophagus Completed NCT00081354
25 Epidemiology of Barrett's Esophagus: A Population Based Study Completed NCT01286155
26 Racial Disparity in Barrett's Esophagus Completed NCT01374074
27 Expression and Function of the Renin-Angiotensin System in the Esophagus Completed NCT02879721 Early Phase 1 Candesartan;Enalapril
28 Barrett&Apos;s Intervention for Dysplasia by Endoscopy Completed NCT01733719
29 Clinical and Molecular Assessment of Men With High Risk for Esophageal Disorders Completed NCT02476513
30 A Comparison of Volumetric Laser Endomicroscopy (VLE) and Endoscopic Mucosal Resection (EMR) in Patients With Barrett's Dysplasia or Intramucosal Adenocarcinoma Completed NCT01862666
31 Nodal Status in Adenocarcinoma of the Esophagus an Cardia Completed NCT01635595
32 Barrett's Esophagus Patient Registry Recruiting NCT01776346
33 Microbiome Involvement With Barrett's Esophagus and Progression to Esophageal Adenocarcinoma Recruiting NCT03216135
34 Prospective Endoscopic Follow-up of Patients With Submucosal Esophageal Adenocarcinoma (The PREFER Trial) Recruiting NCT03222635
35 Impact of an Endoscopic Treatment of the Line Z on the Gastronomic Recurrence and the Gastro- Esophageal Reflux Disease in the Care of the Adenocarcinoma of Barrett's Oesophagus Recruiting NCT03278327
36 ESD for the Treatment of Early Barrett's Neoplasia Recruiting NCT02583087
37 Evaluation of MicroRNA Expression in Blood and Cytology for Detecting Barrett's Esophagus and Associated Neoplasia Recruiting NCT02464930
38 Comparison of Radiofrequency Ablation and Cryotherapy for the Treatment of Barrett's Esophagus With High-Grade Dysplasia and/or Early Adenocarcinoma Recruiting NCT01961778
39 Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry Recruiting NCT00574327
40 Minimally-Invasive Detection of Barrett's Esophagus and Barrett's Esophagus Related Dysplasia/Carcinoma Recruiting NCT02560623
41 The Analysis of WATS3D (Wide Area Transepithelial Sample Biopsy With 3-Dimensional Computer-Assisted Analysis) Increased Yield of Barrett's Esophagus and Esophageal Dysplasia Recruiting NCT03008980
42 Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patients With Low or High Grade Dysplasia, Barrett Esophagus, or Gastroesophageal Reflux Disease Recruiting NCT02890979
43 Influence of Central Obesity on the Esophageal Epithelial Barrier Recruiting NCT02776982
44 Cryotherapy -BEATS-RF Ablation Trial Active, not recruiting NCT01882478
45 Endoscopy Every 2 Years or Only as Needed in Monitoring Patients With Barrett Esophagus Active, not recruiting NCT00987857
46 Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome Active, not recruiting NCT02513784 Chlorhexidine gluconate
47 The Effect of Ablation Therapy on Barrett's Esophagus Enrolling by invitation NCT00587314
48 Endoscopic Mucosal Resection (EMR) in Barrett's Esophagus Enrolling by invitation NCT00586872
49 UNC Barrett's Esophagus and Esophageal Cancer Biorepository Enrolling by invitation NCT02427269
50 The Microenvironment in Barrett's Esophagus Not yet recruiting NCT03060642

Search NIH Clinical Center for Barrett Esophagus/esophageal Adenocarcinoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: barrett esophagus

Genetic Tests for Barrett Esophagus/esophageal Adenocarcinoma

Genetic tests related to Barrett Esophagus/esophageal Adenocarcinoma:

id Genetic test Affiliating Genes
1 Barrett's Esophagus 29
2 Barrett Esophagus 24 MSR1 CTHRC1 ASCC1

Anatomical Context for Barrett Esophagus/esophageal Adenocarcinoma

MalaCards organs/tissues related to Barrett Esophagus/esophageal Adenocarcinoma:

39
Lung, Breast, Skin, Endothelial, Testes, Prostate, Heart

Publications for Barrett Esophagus/esophageal Adenocarcinoma

Variations for Barrett Esophagus/esophageal Adenocarcinoma

ClinVar genetic disease variations for Barrett Esophagus/esophageal Adenocarcinoma:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 MSR1 NM_138715.2(MSR1): c.760C> G (p.Leu254Val) single nucleotide variant Pathogenic rs387906645 GRCh37 Chromosome 8, 16021631: 16021631
2 CTHRC1 NM_138455.3(CTHRC1): c.131A> C (p.Gln44Pro) single nucleotide variant Pathogenic rs387907029 GRCh37 Chromosome 8, 104384015: 104384015
3 ASCC1 NM_001198799.2(ASCC1): c.953A> G (p.Asn318Ser) single nucleotide variant Pathogenic rs146370051 GRCh37 Chromosome 10, 73892817: 73892817

Copy number variations for Barrett Esophagus/esophageal Adenocarcinoma from CNVD:

7 (show top 50) (show all 157)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 18052 1 143700001 144900000 Amplification BCL9 Esophageal adenocarcinoma
2 19685 1 151000001 155000000 Amplification SKI Esophageal adenocarcinoma
3 21958 1 163432534 163614111 Gain and loss LMX1A Barrett''s syndrome
4 25140 1 184717073 186846060 Gain and loss PLA2G4A Barrett''s syndrome
5 25141 1 184717073 186846060 Gain and loss PTGS2 Barrett''s syndrome
6 29301 1 2300000 5400000 Copy number Esophageal adenocarcinoma
7 33578 1 46425202 46624292 Loss RAD54L Barrett''s syndrome
8 37058 1 84900000 107200000 Loss F3 Esophageal adenocarcinoma
9 39044 10 108165938 109275992 Loss SORCS1 Barrett''s syndrome
10 39081 10 109092539 133471230 Loss BUB3 Barrett''s syndrome
11 39082 10 109092539 133471230 Loss C10orf119 Barrett''s syndrome
12 39083 10 109092539 133471230 Loss NANOS1 Barrett''s syndrome
13 39407 10 114856262 115024106 Loss TCF7L2 Barrett''s syndrome
14 47055 10 89500000 92900000 Copy number Esophageal adenocarcinoma
15 49101 11 102900000 110400000 Copy number Esophageal adenocarcinoma
16 50933 11 120168346 133686875 Loss CHEK1 Barrett''s syndrome
17 50934 11 120168346 133686875 Loss ETS1 Barrett''s syndrome
18 50935 11 120168346 133686875 Loss TIRAP Barrett''s syndrome
19 52231 11 149520 6642613 Loss MUC6 Barrett''s syndrome
20 52232 11 149520 6642613 Loss RHOG Barrett''s syndrome
21 53078 11 2400000 5900000 Copy number CDKN1C Esophageal adenocarcinoma
22 54793 11 474042 626401 Loss HRAS Barrett''s syndrome
23 54794 11 474042 626401 Loss MUPCDH Barrett''s syndrome
24 54795 11 474042 626401 Loss RASSF7 Barrett''s syndrome
25 54796 11 474042 626401 Loss RNH1 Barrett''s syndrome
26 54797 11 474042 626401 Loss SCT Barrett''s syndrome
27 57455 11 63400000 77100000 Gain CCND1 Esophageal adenocarcinoma
28 57457 11 63400000 77100000 Gain EMS1 Esophageal adenocarcinoma
29 57458 11 63400000 77100000 Gain FGF3 Esophageal adenocarcinoma
30 60370 11 8555485 8795697 Loss ST5 Barrett''s syndrome
31 60371 11 8555485 8795697 Loss STK33 Barrett''s syndrome
32 64928 12 133416937 133464204 Copy number CHFR Esophageal adenocarcinoma
33 76216 13 28900000 32200000 Gain BRCA2 Esophageal adenocarcinoma
34 80630 13 95000000 115169878 Gain ABCC4 Esophageal adenocarcinoma
35 80631 13 95000000 115169878 Gain ING1 Esophageal adenocarcinoma
36 83864 14 22278370 23705612 Gain and loss MMP14 Barrett''s syndrome
37 83865 14 22278370 23705612 Gain and loss PCK2 Barrett''s syndrome
38 86372 14 58681498 106175506 Gain and loss FOXN3 Barrett''s syndrome
39 86373 14 58681498 106175506 Gain and loss MAX Barrett''s syndrome
40 86374 14 58681498 106175506 Gain and loss MLH3 Barrett''s syndrome
41 92864 15 44800000 63700000 Loss B2M Esophageal adenocarcinoma
42 95624 15 78300000 102531392 Loss IGF1R Esophageal adenocarcinoma
43 105274 16 77215302 77345302 Loss WWOX Barrett''s syndrome
44 105374 16 7900000 10500000 Copy number Esophageal adenocarcinoma
45 106764 17 1 20774742 Copy number MYBBP1A Esophageal adenocarcinoma
46 106765 17 1 20774742 Copy number TP53 Esophageal adenocarcinoma
47 108120 17 18863807 19044654 Loss GRAP Barrett''s syndrome
48 109777 17 2912016 3092354 Gain and loss Barrett''s syndrome
49 109778 17 2912016 3092354 Gain and loss Esophageal adenocarcinoma
50 110805 17 34303536 34308523 Gain SCYA3 Esophageal adenocarcinoma

Expression for Barrett Esophagus/esophageal Adenocarcinoma

Search GEO for disease gene expression data for Barrett Esophagus/esophageal Adenocarcinoma.

Pathways for Barrett Esophagus/esophageal Adenocarcinoma

GO Terms for Barrett Esophagus/esophageal Adenocarcinoma

Biological processes related to Barrett Esophagus/esophageal Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.32 ATP12A ATP4A
2 maintenance of gastrointestinal epithelium GO:0030277 9.26 MUC2 MUC6
3 replicative senescence GO:0090399 9.16 CDKN2A TP53
4 mitotic G1 DNA damage checkpoint GO:0031571 8.96 CCND1 TP53
5 O-glycan processing GO:0016266 8.8 MUC2 MUC5AC MUC6

Molecular functions related to Barrett Esophagus/esophageal Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 sodium:potassium-exchanging ATPase activity GO:0005391 8.96 ATP12A ATP4A
2 hydrogen:potassium-exchanging ATPase activity GO:0008900 8.62 ATP12A ATP4A

Sources for Barrett Esophagus/esophageal Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....